Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma

This study has been completed.
Children's Cancer and Leukaemia Group
Italian Association for Pediatric Hematology Oncology
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: January 28, 2000
Last updated: August 23, 2013
Last verified: April 2008

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying combination chemotherapy and radiation therapy to see how well they work in treating children with localized ependymoma.

Condition Intervention Phase
Brain and Central Nervous System Tumors
Drug: cyclophosphamide
Drug: etoposide
Drug: vincristine sulfate
Procedure: adjuvant therapy
Procedure: conventional surgery
Radiation: radiation therapy
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: SIOP Study of Combined Modality Treatment in Childhood Ependymoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Event-free survival
  • Overall survival
  • Surgical operability
  • Response rate

Estimated Enrollment: 65
Study Start Date: January 1999
Study Completion Date: March 2008
Detailed Description:


  • Determine the event free and overall survival of children with incompletely resected localized ependymoma when treated with adjuvant cyclophosphamide, etoposide, and vincristine followed by radiotherapy.
  • Determine the response rate in these patients to this regimen.

OUTLINE: This is a multicenter study.

Patients undergo surgery to remove as much of tumor as possible. Patients with residual disease proceed to chemotherapy, while those with no residual disease proceed directly to radiotherapy.

Chemotherapy begins within 3 weeks of surgery and consists of vincristine IV on days 1, 8, and 15, cyclophosphamide IV over 3 hours on day 1, and etoposide IV over 4 hours on days 1-3. Treatment repeats every 4 weeks for up to 4 courses. Patients who progress after 2 courses proceed to radiotherapy. If residual disease is still present at completion of chemotherapy, second look surgery is recommended.

Patients undergo radiotherapy daily for 6 weeks beginning after complete resection within 4 weeks of surgery, within 3 weeks of completion of chemotherapy, or within 4 weeks of second look surgery.

Patients are followed at 6 weeks after radiotherapy, every 2 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years.

PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study within 2-3 years.


Ages Eligible for Study:   3 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically proven nonmetastatic intracranial ependymoma

    • Cellular
    • Papillary
    • Clear cell
    • Mixed cell
    • Anaplastic
  • No myxopapillary ependymoma, subependymoma, or ependymoblastoma



  • 3 to 20

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • No hematologic disease that would preclude study participation


  • Not specified


  • No renal disease that would preclude study participation


  • No concurrent unrelated disease that would preclude study participation


Biologic therapy:

  • Not specified


  • No prior chemotherapy

Endocrine therapy:

  • Prior steroids allowed


  • No prior radiotherapy


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004224

Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia
Buenos Aires, Argentina, 1428
Canada, Ontario
Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Fondazione Istituto Nazionale dei Tumori
Milan, Italy, 20133
Erasmus MC - Sophia Children's Hospital
Rotterdam, Netherlands, 3015 GJ
Hospital Des Cruces
Vizcaya, Spain, 48
Ostra Sjukhuset
Gothenburg, Sweden, 41685
United Kingdom
Birmingham Children's Hospital
Birmingham, England, United Kingdom, B4 6NH
Sponsors and Collaborators
Societe Internationale d'Oncologie Pediatrique
Children's Cancer and Leukaemia Group
Italian Association for Pediatric Hematology Oncology
Study Chair: Richard Grundy, MD, PhD Birmingham Children's Hospital
Study Chair: Maura Massimino, MD Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
  More Information Identifier: NCT00004224     History of Changes
Other Study ID Numbers: CDR0000067465
Study First Received: January 28, 2000
Last Updated: August 23, 2013

Keywords provided by National Cancer Institute (NCI):
childhood infratentorial ependymoma
childhood supratentorial ependymoma
newly diagnosed childhood ependymoma

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Topoisomerase II Inhibitors processed this record on April 26, 2017